Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tafluprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Thea Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Prasco Launches Authorized Generic of ZIOPTAN® Ophthalmic Solution
Details : Tafluprost Ophthalmic Solution 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Brand Name : Tafluprost-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 18, 2022
Lead Product(s) : Tafluprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Thea Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?